Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740648 | 1.00 | HPN (0.49) | HPNKDM4EMGLLMAPTMEN1 | |
| SCHEMBL78624 | 0.82 | MAPT (0.51) | KDM4EMAPTKMT2AALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL27883894 | 0.81 | MAPT (0.50) | KDM4EMAPTKMT2AALDH1A1POLB | |
| SCHEMBL11819105 | 0.81 | HPN (0.55) | HPNKDM4EMAPTMEN1KMT2A | |
| SCHEMBL4457140 | 0.80 | HPN (0.51) | HPNKDM4EMGLLMAPTMEN1 | |
| SCHEMBL4553956 | 0.80 | MAPT (0.43) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4431776 | 0.80 | MEN1 (0.36) | KDM4EMGLLMAPTMEN1KMT2A | |
| SCHEMBL3223479 | 0.78 | KMT2A (0.61) | HPNKDM4EMAPTMEN1KMT2A | |
| SCHEMBL2376819 | 0.78 | MAPT (0.60) | KDM4EMGLLMAPTMEN1KMT2A | |
| SCHEMBL20124865 | 0.78 | PIK3CD (0.49) | MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111721858-B | Method for determining genotoxic impurities in rivaroxaban | 杭州华东医药集团新药研究院有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-111721858-A | Method for determining genotoxic impurities in rivaroxaban | 杭州华东医药集团新药研究院有限公司 | 2020-09-29 | — | — | CN | claimed |
| JP-4668903-B2 | — | — | 2011-04-13 | — | — | JP | claimed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | claimed |
| CN-100537549-C | Process for preparing N-aryl morpholinones | MERCK PATENT GMBH (DE) | 2009-09-09 | — | — | CN | claimed |
| JP-2007501818-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | claimed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | claimed |
| CN-1832933-A | Method for production of n-aryl morpholinones | MERCK PATENT GMBH (DE) | 2006-09-13 | — | — | CN | claimed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | claimed |
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218348-A1 | METHOD FOR SYNTHESIZING LACTAM COMPOUNDS | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2022-10-20 | — | — | WO | disclosed |
| CN-111721858-B | Method for determining genotoxic impurities in rivaroxaban | 杭州华东医药集团新药研究院有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| CN-1832933-A | Method for production of n-aryl morpholinones | MERCK PATENT GMBH (DE) | 2006-09-13 | — | — | CN | disclosed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | HPN 581/4885KDM4E 4155/4885MGLL 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.